Intravenous anesthetic combination (hypnotic + opioid)

5 marketed 1 in Phase 3

This page covers all Intravenous anesthetic combination (hypnotic + opioid) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GABA-A receptor (propofol); mu opioid receptor (alfentanil), GABA-A receptor, GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine).

Targets

GABA-A receptor (propofol); mu opioid receptor (alfentanil) · GABA-A receptor · GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine) · GABA-A receptor (propofol); mu-opioid receptor (alfentanil) · NMDA receptor (ketamine); GABA-A receptor (propofol) · GABA-A receptor (propofol); mu-opioid receptor (remifentanil)

Marketed (5)

Phase 3 pipeline (1)

Patent intelligence